The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
EYE on CHINA
Daiichi Sankyo launches Silodosin for the treatment of Dysuria in China
Daiichi Sankyo Company Limited announced that its subsidiary, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd., has begun marketing silodosin (Chinese product name: 优利福®), which was developed for treatment of dysuria associated with benign prostatic hyperplasia.

Silodosin is a selective alpha 1A-adrenoceptor antagonist existing mainly in the prostate which was originally discovered by Kissei Pharmaceutical Co., Ltd. By inhibiting the alpha 1A-adrenergic receptor, silodosin relieves tension in the prostate, lessens pressure and reduces urethral resistance to treat dysuria associated with benign prostatic hyperplasia. Silodosin has been jointly marketed in Japan since May 2006 by Daiichi Sankyo and Kissei Pharmaceutical under the brand name, Urief®.

Through the launch of silodosin and other innovative pharmaceuticals, Daiichi Sankyo is committed to increasing its presence in the fast-growing Chinese pharmaceutical market.

Click here for the complete issue.